Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Other
Hypersensitivity
(2002): Sommer S+, Br J Dermatol 147(2), 266
(1983): Chalmers RJ+, Contact Dermatitis 9(4), 317
(1983): Kuhlwein A+, ZHautkr58(11), 794
Infections
(1999): Zimmermann R+, Ann Dermatol Venereol 126(1), 13
(1990): Prawer SE+, Am Fam Physician 41(5), 1531
CLOFARABINE
Trade name: Clolar (Genzyme)
Indications: Acute lymphoblastic leukemia
Category: Antimetabolite
Half-life: 5.2 hours
Clinically important, potentially hazardous interactions
with: hepatotoxic & nephrotoxic drugs
Reactions
Skin
Acral erythema
(2003): Chiao N+, Leuk Lymphoma 44(8), 1405 (2 cases)
Cellulitis (11%)
Dermatitis (sic) (41%)
Edema (20%)
Erythema (18%)
Hand–foot syndrome
(2005): Faderl S+, Blood 105(3), 940
(2005): Kline JP+, Expert Opin Pharmacother 6(15), 2711
(2003): Chiao N+, Leuk Lymphoma 44(8), 1405 (13%)
Herpes simplex (11%)
Petechiae (29%)
Pruritus (47%)
Rash (sic)
(2005): Faderl S+, Blood 105(3), 940
Xerosis (10%)
Mucosal
Gingival bleeding (15%)
Mucosal inflammation (18%)
Mucositis
(2005): Faderl S+, Blood 105(3), 940
Oral candidiasis (13%)
Stomatitis
(2005): Kline JP+, Expert Opin Pharmacother 6(15), 2711
Other
Abdominal pain (36%)
Cough (19%)
Injection-site pain (14%)
Myalgia/Myositis/Myopathy/Myotoxicity (14%)
(2005): Kline JP+, Expert Opin Pharmacother 6(15), 2711
Pain (19%)
CLOFAZIMINE
Trade names: Clofozine; Hansepran; Lampren; Lamprene
(Novartis); Lapren
Indications: Leprosy
Category: Anti-inflammatory; Antimycobacterial
Half-life: 10 days after a single dose
Clinically important, potentially hazardous interactions
with: fludarabine, pentostatin
Reactions
CLOFAZIMINE 135
Skin
Acne (